RecruitingPhase 2NCT05009992
Combination Therapy for the Treatment of Diffuse Midline Gliomas
Studying Diffuse intrinsic pontine glioma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of California, San Francisco
- Principal Investigator
- Sabine Mueller, MD, PhDUniversity of California, San Francisco
- Intervention
- ONC201(drug)
- Enrollment
- 360 enrolled
- Eligibility
- 2-39 years · All sexes
- Timeline
- 2021 – 2027
Study locations (20)
- University of Alabama at Birmingham, Birmingham, Alabama, United States
- Children's Hospital Los Angeles, Los Angeles, California, United States
- University of California, San Diego / Rady Children's Hospital, San Diego, San Diego, California, United States
- University of California, San Francisco, San Francisco, California, United States
- Children's National Hospital, Washington D.C., District of Columbia, United States
- Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
- Indiana University Riley Children's Hospital, Indianapolis, Indiana, United States
- Johns Hopkins University, Baltimore, Maryland, United States
- Dana-Farber Cancer Institute Harvard University, Boston, Massachusetts, United States
- University of Michigan, Ann Arbor, Michigan, United States
- Children's Hospital Minnesota, Minneapolis, Minnesota, United States
- Washington University in St. Louis, St Louis, Missouri, United States
- Hackensack Meridian Health, Hackensack, New Jersey, United States
- New York University, New York, New York, United States
- Duke University, Durham, North Carolina, United States
- +5 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05009992 on ClinicalTrials.govOther trials for Diffuse intrinsic pontine glioma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07076498Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standard of Care RadiationM.D. Anderson Cancer Center
- RECRUITINGPHASE1, PHASE2NCT07501156H3K27M-specific Immune Effector Cells Targeting DMG/DIPGShenzhen Geno-Immune Medical Institute
- RECRUITINGPHASE2NCT06838676ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade GliomasNationwide Children's Hospital
- RECRUITINGPHASE1NCT06305910CD200AR-L and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent HGG and Newly Diagnosed DMG/DIPG in Children and Young AdultsOX2 Therapeutics
- RECRUITINGPHASE1NCT06221553Safety and Efficacy of Loco-regional B7H3 IL-7Ra CAR T Cell in DIPGChulalongkorn University
- RECRUITINGPHASE1NCT05544526CAR T Cells to Target GD2 for DMGUniversity College, London
- RECRUITINGPHASE1NCT05762419FUS Etoposide for DMGColumbia University
- ACTIVE NOT RECRUITINGPHASE1NCT05768880Study of B7-H3, EGFR806, HER2, And IL13-Zetakine (Quad) CAR T Cell Locoregional Immunotherapy For Pediatric Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, And Recurrent Or Refractory Central Nervous System TumorsSeattle Children's Hospital